Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)

The main purpose of this study is to understand how adults with a new diagnosis of GCA or those with relapsing disease respond to the investigational drug abatacept (also called Orencia). Participants are randomly assigned to receive either abatacept or a placebo. Participants self-administer a weekly subcutaneous injection of abatacept or placebo.

Participants come to the Perelman Center for 8 study visits over 18 months. If during the 18 months, participants do not respond to study treatment or have a relapse, they will have the option to start taking open-label abatacept for 18 months.

ClinicalTrials.gov ID: NCT04474847

Study Duration: Up to 18 months

Disease(s): Giant Cell Arteritis (GCA)